Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note released on Sunday morning. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners upped their price target on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd.

Tonix Pharmaceuticals Trading Down 6.7 %

Shares of TNXP opened at $0.17 on Friday. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $22.14. The firm has a market capitalization of $501,648.00, a P/E ratio of 0.00 and a beta of 2.08. The firm’s 50-day moving average is $0.20 and its two-hundred day moving average is $2.02. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. The company had revenue of $2.21 million during the quarter, compared to analysts’ expectations of $3.50 million. On average, research analysts predict that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC increased its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the period. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. 82.26% of the stock is currently owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.